[go: up one dir, main page]

AR058006A1 - Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos - Google Patents

Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos

Info

Publication number
AR058006A1
AR058006A1 ARP060102414A ARP060102414A AR058006A1 AR 058006 A1 AR058006 A1 AR 058006A1 AR P060102414 A ARP060102414 A AR P060102414A AR P060102414 A ARP060102414 A AR P060102414A AR 058006 A1 AR058006 A1 AR 058006A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
atom
optionally
heteroaryl
Prior art date
Application number
ARP060102414A
Other languages
English (en)
Inventor
Michael Jason Burke
Abdelhakim Hammach
Jennifer A Kowalski
Ingo Andreas Mugge
Mark Stephan Ralph
David S Thomson
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR058006A1 publication Critical patent/AR058006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

Composiciones farmacéuticas que contienen dichos compuestos. Reivindicacion 1: Un compuesto de formula (1) en la que R1 es arilo, heteroarilo o cicloalquilo C3-7 cada uno opcionalmente sustituido independientemente con 1 a 3 grupos sustituyentes seleccionados entre alquilo C1-3, hidroxi, halogeno, oxo, metoxi, amino donde el átomo de N está opcionalmente mono- o disustituido independientemente con un grupo metilo; o tiometilo donde el átomo de S está opcionalmente oxidado en un sulfoxido o sulfona; R2 es H o un halogeno; cada uno de A y B es independientemente CH o N; cada uno de C y E es independientemente un enlace o a -CH2-; D es -CR4R5-, donde R4 es -CF3 y R5 es -OH; y R3 es alquilo C1-6, cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclilo, NR6R7, OR8 o SR9, cada uno opcionalmente sustituido independientemente con 1 a 3 grupos sustituyentes, donde cada grupo sustituyente de R3 es independientemente arilo, heteroarilo, heterociclilo, alquilo C1-5, alquenilo C1-5, cicloalquilo, cicloalquenilo, acilo, alcoxicarbonilo, alcanoiloxi C1-5, alcanoílo C1-5, aroílo, alcanoilamino C1-5, alquilaminocarbonilo, dialquilaminocarbonilo, aminocarboniloxi, alquilaminocarboniloxi C1-5, dialquilaminocarboniloxi C1-5, alcanoilamino C1-5, alcoxicarbonilamino C1-5, alquilsulfonilamino C1-5, aminosulfonilo, alquilaminosulfonilo C1-5, dialquilaminosulfonilo C1-5, alquiloxi C1-5, ariloxi, halogeno, hidroxi, oxo, ciano, trifluorometilo, nitro, carboxilo, aminocarbonilo, amino donde el átomo de N está opcionalmente mono- o disustituido independientemente con un alquilo C1-5 o alquiltio C1-5 donde el átomo de S está opcionalmente oxidado en un sulfoxido o sulfona; donde cada grupo sustituyente de R3 está opcionalmente sustituido independientemente con 1 a 3 sustituyentes seleccionados entre arilo, heteroarilo, heterociclilo, acilo, alquilo C1-5, alcanoiloxi C1-5, alcanoilo C1-5, alcanoilamino C1-5, alquilaminocarbonilo, dialquilaminocarbonilo, alquilsulfonilamino C1-5, aminosulfonilo, alquilaminosulfonilo C1-5, dialquilaminosulfonilo C1-5, alquiloxi C1-5, cicloalquilo C1-5, ariloxi, halogeno, hidroxi, oxo, ciano, trifluorometilo, nitro, aminocarbonilo, amino donde el átomo de N está opcionalmente mono- o disustituido independientemente con un alquilo C1-5 o alquiltio C1-5 donde el átomo de S está opcionalmente oxidado en un sulfoxido o sulfona; donde R6 es un H o alquilo C1-3, y cada uno de R7, R8 y R9 es independientemente alquilo C1-5, alquenilo C1-5, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclilo opcionalmente sustituido independientemente con 1 a 3 grupos sustituyentes, donde cada grupo sustituyente de R7, R8 y R9 es independientemente heteroarilo, heterociclilo, alquilo C1- 5, cicloalquilo, cicloalquenilo, acilo, alcoxicarbonilo, alcanoiloxi C1-5, alcanoílo C1-5, aroílo, alcanoilamino C1-5, alquilaminocarbonilo, dialquilaminocarbonilo, aminocarboniloxi, alquilaminocarboniloxi C1- 5, dialquilaminocarboniloxi C1-5, alcanoilamino C1-5, alcoxicarbonilamino C1-5, alquilsulfonilamino C1-5, aminosulfonilo, alquilaminosulfonilo C1-5, dialquilaminosulfonilo C1-5, alquiloxi C1-5, ariloxi, halogeno, hidroxi, oxo, ciano, trifluorometilo, nitro, aminocarbonilo, amino donde el átomo de N está opcionalmente mono- o disustituido independientemente con un alquilo C1-5 o alquiltio C1-5 donde el átomo de S está opcionalmente oxidado en un sulfoxido o sulfona; donde cada grupo sustituyente de R7, R8 y R9 está opcionalmente sustituido independientemente con 1 a 3 grupos sustituyentes seleccionados entre heteroarilo, heterociclilo, acilo, alquilo C1-5, alcanoilamino C1-5, alquilaminocarbonilo, dialquilaminocarbonilo, alquilsulfonilamino C1-5, aminosulfonilo, alquilaminosulfonilo C1-5, dialquilaminosulfonilo C1-5, alquiloxi C1-5, ariloxi, halogeno, hidroxi, oxo, ciano, trifluorometilo, nitro, aminocarbonilo, amino donde el átomo de N está opcionalmente mono- o disustituido independientemente con un alquilo C1-5 o alquiltio C1-5 donde el átomo de S está opcionalmente oxidado en un sulfoxido o sulfona; o un tautomero, profármaco, solvato o sal del mismo.
ARP060102414A 2005-06-10 2006-06-09 Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos AR058006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68941205P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
AR058006A1 true AR058006A1 (es) 2008-01-23

Family

ID=37057165

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102414A AR058006A1 (es) 2005-06-10 2006-06-09 Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos

Country Status (17)

Country Link
US (1) US7622594B2 (es)
EP (1) EP1893588A1 (es)
JP (1) JP2008543780A (es)
KR (1) KR20080027828A (es)
CN (1) CN101193869B (es)
AR (1) AR058006A1 (es)
AU (1) AU2006257861A1 (es)
BR (1) BRPI0611620A2 (es)
CA (1) CA2610588A1 (es)
IL (1) IL187976A0 (es)
MX (1) MX2007014811A (es)
NZ (1) NZ564696A (es)
PE (1) PE20070112A1 (es)
RU (1) RU2007148225A (es)
TW (1) TW200716573A (es)
WO (1) WO2006135826A1 (es)
ZA (1) ZA200709430B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA011095B1 (ru) * 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
WO2006071609A2 (en) * 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008057857A1 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
CN101547909A (zh) * 2006-12-06 2009-09-30 贝林格尔.英格海姆国际有限公司 糖皮质激素模拟物、其制备方法、药物组合物及其用途
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) * 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
CN101687789A (zh) * 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
US8143280B2 (en) * 2007-09-27 2012-03-27 Hoffmann-La Roche Inc. Glucocorticoid receptor antagonists
WO2009069736A1 (ja) * 2007-11-28 2009-06-04 Kyowa Hakko Kirin Co., Ltd. 含窒素化合物
TWI445705B (zh) * 2008-05-20 2014-07-21 Astrazeneca Ab 經苯基及苯并二基取代之吲唑衍生物
BRPI0915680A2 (pt) 2008-06-06 2019-09-24 Boehringer Ingelheim Int miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
US8138189B2 (en) * 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201321740D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN104829591B (zh) * 2015-04-27 2017-05-03 梯尔希（南京）药物研发有限公司 氘代匹莫齐特的制备方法
WO2017161518A1 (en) * 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
JP6864379B2 (ja) 2016-03-31 2021-04-28 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インドール類似体及びその使用
EP3936192B1 (en) 2019-03-06 2025-04-09 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
CA3187566A1 (en) * 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
US20250136548A1 (en) * 2022-01-20 2025-05-01 Terran Biosciences Inc. Functionalized alkylamines
CN117069629A (zh) * 2023-07-27 2023-11-17 五邑大学 一种含硫乙酰胺类化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856475A1 (de) 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
CA2472746A1 (en) * 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
PL373043A1 (en) * 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2477764A1 (en) * 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003297471A1 (en) * 2003-01-03 2004-08-10 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200523503A (en) * 2003-09-29 2005-07-16 Sony Corp Backlight, light guiding plate, method for manufacturing diffusion plate and light guiding plate, and liquid crystal display device

Also Published As

Publication number Publication date
EP1893588A1 (en) 2008-03-05
CN101193869A (zh) 2008-06-04
CN101193869B (zh) 2011-03-02
JP2008543780A (ja) 2008-12-04
IL187976A0 (en) 2008-03-20
CA2610588A1 (en) 2006-12-21
TW200716573A (en) 2007-05-01
RU2007148225A (ru) 2009-07-20
ZA200709430B (en) 2008-11-26
PE20070112A1 (es) 2007-03-08
NZ564696A (en) 2011-05-27
MX2007014811A (es) 2008-02-14
US7622594B2 (en) 2009-11-24
KR20080027828A (ko) 2008-03-28
BRPI0611620A2 (pt) 2009-01-13
US20070060633A1 (en) 2007-03-15
WO2006135826A1 (en) 2006-12-21
AU2006257861A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
AR058006A1 (es) Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos
AR046020A1 (es) Mimeticos de glucocorticoides, metodos de preparacion, composiciones farmaceuticas y usos de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR071856A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
AR068061A1 (es) Derivados de bisamida biciclicos utiles como pesticidas
AR065280A1 (es) Agentes antiparasitarios
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
AR039140A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR059178A1 (es) Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.
AR066014A1 (es) Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos.
AR062526A1 (es) DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR068367A1 (es) Derivados de amidas con actividad fungicida
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal